연구동향 분석
박사

Hyaluronic Acid-Based Nanomedicines for Tumor-Targeted Therapy : 암 표적치료를 위한 히알루론산 기반 나노의약품에 대한 연구

윤홍열 2015년

논문상세정보
인용/피인용
' Hyaluronic Acid-Based Nanomedicines for Tumor-Targeted Therapy : 암 표적치료를 위한 히알루론산 기반 나노의약품에 대한 연구' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • drug delivery
  • hyaluronic acid (ha)
  • nanomedicine
  • targeted-therapy
  • tumor-targeting
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
112 0

0.0%

' Hyaluronic Acid-Based Nanomedicines for Tumor-Targeted Therapy : 암 표적치료를 위한 히알루론산 기반 나노의약품에 대한 연구' 의 참고문헌

  • Zugates GT, Anderson DG, Little SR, Lawhorn IEB, Langer R. Synthesis of Poly(β-amino ester)s with Thiol-Reactive Side Chains for DNA Delivery. J Am Chem Soc. 2006;128:12726-34.
  • Zhu C, Jung S, Luo S, Meng F, Zhu X, Park TG, et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA?PCL?PDMAEMA triblock copolymers. Biomaterials. 2010;31:2408-16.
  • Zhou J, Wu J, Hafdi N, Behr J-P, Erbacher P, Peng L. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun. 2006;0:2362-4.
  • Zhang Z, Tongchusak S, Mizukami Y, Kang YJ, Ioji T, Touma M, et al. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials. 2011;32:3666-78.
  • Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in Medicine: Therapeutic Applications and Developments. Clinical Pharmacology & Therapeutics. 2008;83:761-9.
  • Zhang C, Tang N, Liu X, Liang W, Xu W, Torchilin VP. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release. 2006;112:229-39.
  • Yu MK, Jeong YY, Park J, Park S, Kim JW, Min JJ, et al. Drug-Loaded Superparamagnetic Iron Oxide Nanoparticles for Combined Cancer Imaging and Therapy In Vivo. Angewandte Chemie International Edition. 2008;47:5362-5.
  • You Y-Z, Manickam DS, Zhou Q-H, Oupicky D. Reducible poly(2-dimethylaminoethyl methacrylate): Synthesis, cytotoxicity, and gene delivery activity. J Control Release. 2007;122:217-25.
  • Yoon HY, Son S, Lee SJ, You DG, Yhee JY, Park JH, et al. Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA. Scientific reports. 2014;4.
  • Yoon HY, Koo H, Choi KY, Lee SJ, Kim K, Kwon IC, et al. Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials. 2012;33:3980-9.
  • Yoon HY, Koo H, Choi KY, Chan Kwon I, Choi K, Park JH, et al. Photo-crosslinked hyaluronic acid nanoparticles with improved stability for in vivo tumor-targeted drug delivery. Biomaterials. 2013;34:5273-80.
  • Yoon HY, Kim HR, Saravanakumar G, Heo R, Chae SY, Um W, et al. Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting. Journal of controlled release : official journal of the Controlled Release Society. 2013;172:653-61.
  • Yi DK, Sun I-C, Ryu JH, Koo H, Park CW, Youn I-C, et al. Matrix metalloproteinase sensitive gold nanorod for simultaneous bioimaging and photothermal therapy of cancer. Bioconj Chem. 2010;21:2173-7.
  • Yerushalmi N, Arad A, Margalit R. Molecular and Cellular Studies of Hyaluronic Acid-Modified Liposomes as Bioadhesive Carriers for Topical Drug Delivery in Wound Healing. Archives of Biochemistry and Biophysics. 1994;313:267-73.
  • Yague E, Higgins C, Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Therapy. 2004;11:1170-4.
  • Yadav AK, Mishra P, Mishra AK, Mishra P, Jain S, Agrawal GP. Development and characterization of hyaluronic acid?anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine: Nanotechnology, Biology and Medicine. 2007;3:246-57.
  • Xie J, Liu G, Eden HS, Ai H, Chen X. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res. 2011;44:883-92.
  • Xiao K, Luo J, Fowler WL, Li Y, Lee JS, Xing L, et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials. 2009;30:6006-16.
  • Wu H, Hait WN, Yang J-M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer research. 2003;63:1515-9.
  • Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129-38.
  • Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol. 2001;19:316-7.
  • Wang SJ, Wong G, de Heer A-M, Xia W, Bourguignon LYW. CD44 variant isoforms in head and neck squamous cell carcinoma progression. The Laryngoscope. 2009;119:1518-30.
  • Wang AZ, Langer R, Farokhzad OC. Nanoparticle Delivery of Cancer Drugs. Annual Review of Medicine. 2012;63:185-98.
  • Verbaan FJ, Oussoren C, van Dam IM, Takakura Y, Hashida M, Crommelin DJA, et al. The fate of poly(2-dimethyl amino ethyl)methacrylate-based polyplexes after intravenous administration. Int J Pharm. 2001;214:99-101.
  • Verbaan FJ, Oussoren C, Snel CJ, Crommelin DJA, Hennink WE, Storm G. Steric stabilization of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes mediates prolonged circulation and tumor targeting in mice. The Journal of Gene Medicine. 2004;6:64-75.
  • Verbaan FJ, Klouwenberg PK, Steenis JHv, Snel CJ, Boerman O, Hennink WE, et al. Application of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes for gene transfer into human ovarian carcinoma cells. Int J Pharm. 2005;304:185-92.
  • Venkataraman S, Ong WL, Ong ZY, Joachim Loo SC, Rachel Ee PL, Yang YY. The role of PEG architecture and molecular weight in the gene transfection performance of PEGylated poly(dimethylaminoethyl methacrylate) based cationic polymers. Biomaterials. 2011;32:2369-78.
  • Varghese OP, Sun W, Hilborn J, Ossipov DA. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach. J Am Chem Soc. 2009;131:8781-3.
  • Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131-5.
  • Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nature reviews Cancer. 2004;4:528-39.
  • Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528-39.
  • Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. The Journal of experimental medicine. 1999;190:1669-78.
  • Thakare VS, Das M, Jain AK, Patil S, Jain S. Carbon nanotubes in cancer theragnosis. Nanomedicine. 2010;5:1277-301.
  • Tamakoshi K, Kikkawa F, Maeda O, Suganuma N, Yamagata S, Yamagata T, et al. Hyaluronidase activity in gynaecological cancer tissues with different metastatic forms. Br J Cancer. 1997;75:1807-11.
  • Takimoto CH, Calvo E. Principles of oncologic pharmacotherapy. Cancer Management: A Multidisciplinary Approach. 2008;11.
  • Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. J Control Release. 2009;137:234-40.
  • Taetz S, Bochot A, Surace C, Arpicco S, Renoir JM, Schaefer UF, et al. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells. Oligonucleotides. 2009;19:103-16.
  • Szarpak A, Cui D, Dubreuil Fdr, De Geest BG, De Cock LJ, Picart C, et al. Designing hyaluronic acid-based layer-by-layer capsules as a aarrier for intracellular drug delivery. Biomacromolecules. 2010;11:713-20.
  • Swierczewska M, Choi KY, Mertz EL, Huang X, Zhang F, Zhu L, et al. A Facile, One-Step Nanocarbon Functionalization for Biomedical Applications. Nano Letters. 2012;12:3613-20.
  • Surace C, Arpicco S, Dufay-Wojcicki A, Marsaud V, Bouclier C, Clay D, et al. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. Mol Pharm. 2009;6:1062-73.
  • Sugiyama M, Woodman A, Sugino T, Crowley S, Ho K, Smith J, et al. Non-invasive detection of bladder cancer by identification of abnormal CD44 proteins in exfoliated cancer cells in urine. Clinical Molecular Pathology. 1995;48:M142-M7.
  • Stewart BW, Wild C, International Agency for Research on Cancer, World Health Organization. World cancer report 2014. Lyon, France Geneva, Switzerland: International Agency for Research on Cancer, WHO Press; 2014.
  • Stern R, Jedrzejas MJ. Hyaluronidases: Their genomics, structures, and mechanisms of action. Chem Rev. 2006;106:818-39.
  • Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood. 2001;98:1070-7.
  • Son S, Namgung R, Kim J, Singha K, Kim WJ. Bioreducible Polymers for Gene Silencing and Delivery. Acc Chem Res. 2011;45:1100-12.
  • Serafino A, Zonfrillo M, Andreola F, Psaila R, Mercuri L, Moroni N, et al. CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. Curr Cancer Drug Targets. 2011;11:572-85.
  • Saravanakumar G, Choi KY, Yoon HY, Kim K, Park JH, Kwon IC, et al. Hydrotropic hyaluronic acid conjugates: Synthesis, characterization, and implications as a carrier of paclitaxel. Int J Pharm. 2010;394:154-61.
  • Ryu JH, Lee A, Chu J-U, Koo H, Ko C-Y, Kim HS, et al. Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic matrix metalloproteinase 3?specific polymeric probe. Arthritis Rheum. 2011;63:3824-32.
  • Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annual review of immunology. 2002;20:323-70.
  • Rungsardthong U, Deshpande M, Bailey L, Vamvakaki M, Armes SP, Garnett MC, et al. Copolymers of amine methacrylate with poly(ethylene glycol) as vectors for gene therapy. J Control Release. 2001;73:359-80.
  • Rosato A, Banzato A, De Luca G, Renier D, Bettella F, Pagano C, et al. HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol Oncol. 2006;24:207-15.
  • Rocha PN, Plumb TJ, Crowley SD, Coffman TM. Effector mechanisms in transplant rejection. Immunological reviews. 2003;196:51-64.
  • Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature reviews Immunology. 2012;12:269-81.
  • Ranuncolo SM, Ladeda V, Specterman S, Varela M, Lastiri J, Morandi A, et al. CD44 expression in human gliomas. Journal of Surgical Oncology. 2002;79:30-6.
  • Rand TA, Ginalski K, Grishin NV, Wang X. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc Natl Acad Sci U S A. 2004;101:14385-9.
  • Puskas I, Szemjonov A, Fenyvesi E, Malanga M, Szente L. Aspects of determining the molecular weight of cyclodextrin polymers and oligomers by static light scattering. Carbohydr Polym. 2013;94:124-8.
  • Prabaharan M, Mano JF. Chitosan-Based Particles as Controlled Drug Delivery Systems. Drug Delivery. 2004;12:41-57.
  • Platt VM, Szoka FC. Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm. 2008;5:474-86.
  • Platt VM, Szoka FC, Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Molecular pharmaceutics. 2008;5:474-86.
  • Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nature reviews Drug discovery. 2010;9:615-27.
  • Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9:615-27.
  • Peer D, Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia. 2004;6:343-53.
  • Peer D, Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer. 2004;108:780-9.
  • Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology. 2007;2:751-60.
  • Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nano. 2007;2:751-60.
  • Park W, Park S-j, Na K. The controlled photoactivity of nanoparticles derived from ionic interactions between a water soluble polymeric photosensitizer and polysaccharide quencher. Biomaterials. 2011;32:8261-70.
  • Park W, Park S-j, Na K. Potential of self-organizing nanogel with acetylated chondroitin sulfate as an anti-cancer drug carrier. Colloids and Surfaces B: Biointerfaces. 2010;79:501-8.
  • Park TG, Jeong JH, Kim SW. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev. 2006;58:467-86.
  • Park K, Lee S, Kang E, Kim K, Choi K, Kwon IC. New generation of multifunctional nanoparticles for cancer imaging and therapy. Adv Funct Mater. 2009;19:1553-66.
  • Park JH, Lee S, Kim J-H, Park K, Kim K, Kwon IC. Polymeric nanomedicine for cancer therapy. Progress in Polymer Science. 2008;33:113-37.
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer. 2012;12:252-64.
  • Oishi M, Nagasaki Y, Itaka K, Nishiyama N, Kataoka K. Lactosylated Poly(ethylene glycol)-siRNA Conjugate through Acid-Labile β-Thiopropionate Linkage to Construct pH-Sensitive Polyion Complex Micelles Achieving Enhanced Gene Silencing in Hepatoma Cells. J Am Chem Soc. 2005;127:1624-5.
  • Oh Y-K, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009;61:850-62.
  • Ogris M, Brunner S, Schuller S, Kircheis R, Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 1999;6:595-605.
  • Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn E, et al. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut. 2005;54:1298-308.
  • Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS letters. 2003;545:144-50.
  • Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, et al. Multifunctional Polymeric Micelles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems. Nano Letters. 2006;6:2427-30.
  • Nanda NK, Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell. 1995;82:13-7.
  • Nagabhushan M, Pretlow TG, Guo YJ, Amini SB, Pretlow TP, Sy MS. Altered expression of CD44 in human prostate cancer during progression. Am J Clin Pathol. 1996;106:647-51.
  • Na K, Lee KH, Bae YH. pH-sensitivity and pH-dependent interior structural change of self-assembled hydrogel nanoparticles of pullulan acetate/oligo-sulfonamide conjugate. J Control Release. 2004;97:513-25.
  • Na JH, Koo H, Lee S, Min KH, Park K, Yoo H, et al. Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models. Biomaterials. 2011;32:5252-61.
  • Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nature materials. 2013;12:991-1003.
  • Morgan J, Oseroff AR. Mitochondria-based photodynamic anti-cancer therapy. Adv Drug Deliv Rev. 2001;49:71-86.
  • Mok H, Park JW, Park TG. Antisense Oligodeoxynucleotide-Conjugated Hyaluronic Acid/Protamine Nanocomplexes for Intracellular Gene Inhibition. Bioconjugate Chemistry. 2007;18:1483-9.
  • Mok H, Lee SH, Park JW, Park TG. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat Mater. 2010;9:272-8.
  • Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran?doxorubicin conjugate using chitosan nanoparticles as carrier. Journal of Controlled Release. 2001;74:317-23.
  • Mishra S, Webster P, Davis ME. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol. 2004;83:97-111.
  • Matsumoto S, Christie RJ, Nishiyama N, Miyata K, Ishii A, Oba M, et al. Environment-Responsive Block Copolymer Micelles with a Disulfide Cross-Linked Core for Enhanced siRNA Delivery. Biomacromolecules. 2008;10:119-27.
  • Masereeuw R, Russel FGM. Mechanisms and clinical implications of renal drug excretion. Drug Metab Rev. 2001;33:299-351.
  • Malmberg K-J. Effective immunotherapy against cancer. Cancer Immunol Immunother. 2004;53:879-92.
  • Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of controlled release : official journal of the Controlled Release Society. 2000;65:271-84.
  • Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271-84.
  • Madan AK, Yu K, Dhurandhar N, Cullinane C, Pang Y, Beech DJ. Association of hyaluronidase and breast adenocarcinoma invasiveness. Oncol Rep. 1999;6:607-9.
  • Madan AK, Pang Y, Wilkiemeyer MB, Yu D, Beech DJ. Increased hyaluronidase expression in more aggressive prostate adenocarcinoma. Oncol Rep. 1999;6:1431-3.
  • Luo Y, Prestwich GD. Synthesis and Selective Cytotoxicity of a Hyaluronic Acid?Antitumor Bioconjugate. Bioconjugate Chemistry. 1999;10:755-63.
  • Lovell JF, Liu TWB, Chen J, Zheng G. Activatable photosensitizers for imaging and therapy. Chem Rev. 2010;110:2839-57.
  • Lokeshwar VB, Soloway MS, Block NL. Secretion of bladder tumor-derived hyaluronidase activity by invasive bladder tumor cells. Cancer Lett. 1998;131:21-7.
  • Lokeshwar BL, Lokeshwar VB, Block NL. Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. Anticancer research. 1995;15:1191-8.
  • Liu G, Choi KY, Bhirde A, Swierczewska M, Yin J, Lee SW, et al. Sticky nanoparticles: a platform for siRNA delivery by a bis(zinc(II) dipicolylamine)-functionalized, self-assembled nanoconjugate. Angewandte Chemie (International ed in English). 2012;51:445-9.
  • Liu D, Pearlman E, Diaconu E, Guo K, Mori H, Haqqi T, et al. Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci U S A. 1996;93:7832-7.
  • Ling X, Li F. Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques. 2004;36:450-63.
  • Lin H, Rathmell JC, Gray GS, Thompson CB, Leiden JM, Alegre ML. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. The Journal of experimental medicine. 1998;188:199-204.
  • Li Y, Hindi K, Watts KM, Taylor JB, Zhang K, Li Z, et al. Shell crosslinked nanoparticles carrying silver antimicrobials as therapeutics. Chem Commun. 2010;46:121-3.
  • Li J, Huo M, Wang J, Zhou J, Mohammad JM, Zhang Y, et al. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials. 2012;33:2310-20.
  • Li F, Na K. Self-Assembled Chlorin e6 Conjugated Chondroitin Sulfate Nanodrug for Photodynamic Therapy. Biomacromolecules. 2011;12:1724-30.
  • Lepperdinger G, Strobl B, Kreil G. HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. J Biol Chem. 1998;273:22466-70.
  • Lee SJ, Park K, Oh Y-K, Kwon S-H, Her S, Kim I-S, et al. Tumor specificity and therapeutic efficacy of photosensitizer-encapsulated glycol chitosan-based nanoparticles in tumor-bearing mice. Biomaterials. 2009;30:2929-39.
  • Lee SJ, Koo H, Lee D-E, Min S, Lee S, Chen X, et al. Tumor-homing photosensitizer-conjugated glycol chitosan nanoparticles for synchronous photodynamic imaging and therapy based on cellular on/off system. Biomaterials. 2011;32:4021-9.
  • Lee SJ, Koo H, Jeong H, Huh MS, Choi Y, Jeong SY, et al. Comparative study of photosensitizer loaded and conjugated glycol chitosan nanoparticles for cancer therapy. J Control Release. 2011;152:21-9.
  • Lee SJ, Huh MS, Lee SY, Min S, Lee S, Koo H, et al. Tumor-Homing Poly-siRNA/Glycol Chitosan Self-Cross-Linked Nanoparticles for Systemic siRNA Delivery in Cancer Treatment. Angew Chem Int Ed. 2012;51:7203-7.
  • Lee S, Park K, Kim K, Choi K, Kwon IC. Activatable imaging probes with amplified fluorescent signals. Chem Commun (Camb). 2008:4250-60.
  • Lee HJ, Kim SE, Kwon IK, Park C, Kim C, Yang J, et al. Spatially mineralized self-assembled polymeric nanocarriers with enhanced robustness and controlled drug-releasing property. Chem Commun. 2010;46:377-9.
  • Lee H, Mok H, Lee S, Oh Y-K, Park TG. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. Journal of Controlled Release. 2007;119:245-52.
  • Lee H, Lee K, Park TG. Hyaluronic Acid - Paclitaxel Conjugate Micelles: Synthesis, Characterization, and Antitumor Activity. Bioconjugate Chemistry. 2008;19:1319-25.
  • Lee D-E, Koo H, Sun I-C, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev. 2012;41:2656-72.
  • Lee D-E, Kim A, Saravanakumar G, Koo H, Kwon I, Choi K, et al. Hyaluronidase-sensitive SPIONs for MR/optical dual imaging nanoprobes. Macromol. Res. 2011;19:861-7.
  • Lapcik L Jr., Lapsik L, De Smedt S, Demeester J, Chabrecek P. Hyaluronan: Preparation, structure, properties, and applications. Chem Rev. 1998;98:2663-84.
  • Lapc?ik L, De Smedt S, Demeester J, Chabrec?ek P. Hyaluronan: Preparation, structure, properties, and applications. Chem Rev. 1998;98:2663-84.
  • Lammers T, Subr V, Ulbrich K, Hennink WE, Storm G, Kiessling F. Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. Nano Today. 2010;5:197-212.
  • Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011;44:1029-38.
  • Lakshman M, Subramaniam V, Rubenthiran U, Jothy S. CD44 promotes resistance to apoptosis in human colon cancer cells. Experimental and Molecular Pathology. 2004;77:18-25.
  • Kunze D, Wuttig D, Fuessel S, Kraemer K, Kotzsch M, Meye A, et al. Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-XL) in bladder cancer cells. Anticancer research. 2008;28:2259-63.
  • Kunze D, Kraemer K, Erdmann K, Froehner M, Wirth MP, Fuessel S. Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. International journal of oncology. 2012;41:1271-7.
  • Kramer MW, Escudero DO, Lokeshwar SD, Golshani R, Ekwenna OO, Acosta K, et al. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer. 2011;117:1197-209.
  • Koo H, Moon H, Han H, Na JH, Huh MS, Park JH, et al. The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials. 2012;33:3485-93.
  • Koo H, Lee S, Na JH, Kim SH, Hahn SK, Choi K, et al. Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles. Angew Chem Int Ed Engl. 2012;51:11836-40.
  • Koo H, Lee H, Lee S, Min KH, Kim MS, Lee DS, et al. In vivo tumor diagnosis and photodynamic therapy via tumoral pH-responsive polymeric micelles. Chem Commun. 2010;46:5668-70.
  • Koo H, Huh MS, Sun I-C, Yuk SH, Choi K, Kim K, et al. In vivo targeted delivery of nanoparticles for theranosis. Acc Chem Res. 2011;44:1018-28.
  • Koo H, Huh MS, Ryu JH, Lee D-E, Sun I-C, Choi K, et al. Nanoprobes for biomedical imaging in living systems. Nano Today. 2011;6:204-20.
  • Koo AN, Min KH, Lee HJ, Lee S-U, Kim K, Chan Kwon I, et al. Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links. Biomaterials. 2012;33:1489-99.
  • Kong W-H, Sung D-K, Shim Y-H, Bae KH, Dubois P, Park TG, et al. Efficient intracellular siRNA delivery strategy through rapid and simple two steps mixing involving noncovalent post-PEGylation. J Control Release. 2009;138:141-7.
  • Kobayashi H, Choyke PL. Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res. 2010;44:83-90.
  • Klingbeil P, Natrajan R, Everitt G, Vatcheva R, Marchio C, Palacios J, et al. CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Research and Treatment. 2010;120:95-109.
  • Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release. 2006;116:123-9.
  • Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release. 2008;129:107-16.
  • Kim RA, Wang JC. Function of DNA topoisomerases as replication swivels in Saccharomyces cerevisiae. Journal of Molecular Biology. 1989;208:257-67.
  • Kim JH, Kang TH, Noh KH, Kim SH, Lee YH, Kim KW, et al. Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN. Immunology letters. 2010;134:47-54.
  • Kim JH, Kang TH, Noh KH, Bae HC, Kim SH, Yoo YD, et al. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunology letters. 2009;122:58-67.
  • Kim H, Mun S, Choi Y. Photosensitizer-conjugated polymeric nanoparticles for redox-responsive fluorescence imaging and photodynamic therapy. Journal of Materials Chemistry B. 2013;1:429-31.
  • Kim DW, Kim K-O, Shin MJ, Ha JH, Seo SW, Yang J, et al. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer. 2009;8:28-38.
  • Kichler A, Chillon M, Leborgne C, Danos O, Frisch Bt. Intranasal gene delivery with a polyethylenimine?PEG conjugate. J Control Release. 2002;81:379-88.
  • Kang TH, Lee JH, Song CK, Han HD, Shin BC, Pai SI, et al. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer research. 2007;67:802-11.
  • Jiang T, Zhang Z, Zhang Y, Lv H, Zhou J, Li C, et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials. 2012;33:9246-58.
  • Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Advanced Drug Delivery Reviews. 2001;47:83-97.
  • Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653-64.
  • Itano N. Simple primary structure, complex turnover regulation and multiple roles of hyaluronan. J Biochem. 2008;144:131-7.
  • Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc- and thereby promotes tumor growth. Cancer Cell. 2011;19:387-400.
  • Iida N, Bourguignon LYW. New CD44 splice variants associated with human breast cancers. Journal of Cellular Physiology. 1995;162:127-33.
  • Hu J, Qian Y, Wang X, Liu T, Liu S. Drug-Loaded and Superparamagnetic Iron Oxide Nanoparticle Surface-Embedded Amphiphilic Block Copolymer Micelles for Integrated Chemotherapeutic Drug Delivery and MR Imaging. Langmuir. 2011;28:2073-82.
  • Houghton AN. Cancer antigens: immune recognition of self and altered self. The Journal of Experimental Medicine. 1994;180:1-4.
  • Han S-Y, Han HS, Lee SC, Kang YM, Kim I-S, Park JH. Mineralized hyaluronic acid nanoparticles as a robust drug carrier. J Mater Chem. 2011;21:7996-8001.
  • Han M, Lv Q, Tang X-J, Hu Y-L, Xu D-H, Li F-Z, et al. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. Journal of Controlled Release. 2012;163:136-44.
  • Han HS, Lee J, Kim HR, Chae SY, Kim M, Saravanakumar G, et al. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: Mineralization and its effect on tumor targetability in vivo. J Control Release. 2013;168:105-14.
  • Han HS, Choi KY, Ko H, Jeon J, Saravanakumar G, Suh YD, et al. Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy. J Control Release. 2015;200:158-66.
  • Gurinovich GP, Zorina TE, Melnov SB, Melnova NI, Gurinovich IF, Grubina LA, et al. Photodynamic activity of chlorin e6 and chlorin e6 ethylenediamide in vitro and in vivo. J Photochem Photobiol B: Biol. 1992;13:51-7.
  • Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annual review of immunology. 2002;20:621-67.
  • Galer CE, Sano D, Ghosh SC, Hah JH, Auzenne E, Hamir AN, et al. Hyaluronic acid-paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism. Oral Oncol. 2011;47:1039-47.
  • Funhoff AM, Monge S, Teeuwen R, Koning GA, Schuurmans-Nieuwenbroek NME, Crommelin DJA, et al. PEG shielded polymeric double-layered micelles for gene delivery. J Control Release. 2005;102:711-24.
  • Frost GI, Csoka TB, Wong T, Stern R. Purification, Cloning, and Expression of Human Plasma Hyaluronidase. Biochemical and Biophysical Research Communications. 1997;236:10-5.
  • Friedl P, den Boer AT, Gunzer M. Tuning immune responses: diversity and adaptation of the immunological synapse. Nature reviews Immunology. 2005;5:532-45.
  • Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annual review of immunology. 2000;18:245-73.
  • Felt O, Buri P, Gurny R. Chitosan: A Unique Polysaccharide for Drug Delivery. Drug development and industrial pharmacy. 1998;24:979-93.
  • Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-8.
  • Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6:688-701.
  • Delcea M, Mohwald H, Skirtach AG. Stimuli-responsive LbL capsules and nanoshells for drug delivery. Adv Drug Del Rev. 2011;63:730-47.
  • De Stefano I, Battaglia A, Zannoni GF, Prisco MG, Fattorossi A, Travaglia D, et al. Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemother Pharmacol. 2011;68:107-16.
  • Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7:771-82.
  • Datir SR, Das M, Singh RP, Jain S. Hyaluronate Tethered, “Smart” Multiwalled Carbon Nanotubes for Tumor-Targeted Delivery of Doxorubicin. Bioconjugate Chemistry. 2012;23:2201-13.
  • Dams ETM, Laverman P, Oyen WJG, Storm G, Scherphof GL, van der Meer JWM, et al. Accelerated Blood Clearance and Altered Biodistribution of Repeated Injections of Sterically Stabilized Liposomes. J Pharmacol Exp Ther. 2000;292:1071-9.
  • Convertine AJ, Benoit DSW, Duvall CL, Hoffman AS, Stayton PS. Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release. 2009;133:221-9.
  • Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011:313-9.
  • Choi KY, Yoon HY, Kim JH, Bae SM, Park RW, Kang YM, et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano. 2011;5:8591-9.
  • Choi KY, Saravanakumar G, Park JH, Park K. Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids and surfaces B, Biointerfaces. 2012;99:82-94.
  • Choi KY, Saravanakumar G, Park JH, Park K. Hyaluronic acid-based nanocarriers for intracellular targeting: Interfacial interactions with proteins in cancer. Colloids Surf B Biointerfaces. 2012;99:82-94.
  • Choi KY, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials. 2011;32:1880-9.
  • Choi KY, Min KH, Na JH, Choi K, Kim K, Park JH, et al. Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution. Journal of Materials Chemistry. 2009;19:4102-7.
  • Choi KY, Min KH, Na JH, Choi K, Kim K, Park JH, et al. Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution. J Mater Chem. 2009;19:4102-7.
  • Choi KY, Jeon EJ, Yoon HY, Lee BS, Na JH, Min KH, et al. Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials. 2012;33:6186-93.
  • Choi KY, Chung H, Min KH, Yoon HY, Kim K, Park JH, et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials. 2010;31:106-14.
  • Chen Y, Sen J, Bathula SR, Yang Q, Fittipaldi R, Huang L. Novel Cationic Lipid That Delivers siRNA and Enhances Therapeutic Effect in Lung Cancer Cells. Mol Pharm. 2009;6:696-705.
  • Chen AM, Zhang M, Wei D, Stueber D, Taratula O, Minko T, et al. Co?delivery of Doxorubicin and Bcl?2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug?Resistant Cancer Cells. Small. 2009;5:2673-7.
  • Celli JP, Spring BQ, Rizvi I, Evans CL, Samkoe KS, Verma S, et al. Imaging and photodynamic therapy: Mechanisms, monitoring, and optimization. Chem Rev. 2010;110:2795-838.
  • Cai S, Thati S, Bagby TR, Diab HM, Davies NM, Cohen MS, et al. Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. J Control Release. 2010;146:212-8.
  • Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced drug delivery reviews. 2008;60:1615-26.
  • Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615-26.
  • Burgdorf S, Kurts C. Endocytosis mechanisms and the cell biology of antigen presentation. Current opinion in immunology. 2008;20:89-95.
  • Brill SJ, Sternglanz R. Transcription-dependent DNA supercoiling in yeast DNA topoisomerase mutants. Cell. 1988;54:403-11.
  • Bourzac K. Nanotechnology: Carrying drugs. Nature. 2012;491:S58-60.
  • Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Advanced Drug Delivery Reviews. 2010;62:83-99.
  • Bertrand P, Girard N, Duval C, d'Anjou J, Chauzy C, Menard J-F, et al. Increased hyaluronidase levels in breast tumor metastases. International Journal of Cancer. 1997;73:327-31.
  • Benichou G, Takizawa PA, Olson CA, McMillan M, Sercarz EE. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. The Journal of experimental medicine. 1992;175:305-8.
  • Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006;34:322-33.
  • Banzato A, Rondina M, Melendez-Alafort L, Zangoni E, Nadali A, Renier D, et al. Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. Nucl Med Biol. 2009;36:525-33.
  • Bae YH, Yin H. Stability issues of polymeric micelles. J Control Release. 2008;131:2-4.
  • B. Zhou, J.A. Weigel, L. Fauss, P.H. Weigel, Identification of the hyaluronan receptor for endocytosis (HARE), J Biol Chem 275 (2000) 37733?37741.
  • Arpicco S, Milla P, Stella B, Dosio F. Hyaluronic acid conjugates as vectors for the active targeting of drugs, genes and nanocomposites in cancer treatment. Molecules. 2014;19:3193-230.
  • Anderson BC, Mallapragada SK. Synthesis and characterization of injectable, water-soluble copolymers of tertiary amine methacrylates and poly(ethylene glycol) containing methacrylates. Biomaterials. 2002;23:4345-52.
  • Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles. Mol Pharm. 2008;5:505-15.
  • Agarwal S, Zhang Y, Maji S, Greiner A. PDMAEMA based gene delivery materials. Mater Today. 2012;15:388-93.
  • Aagaard L, Rossi JJ. RNAi therapeutics: Principles, prospects and challenges. Adv Drug Deliv Rev. 2007;59:75-86.